Clinical Trial Update: Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 trial investigating durvalumab with ablative radiation for small-cell lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: University of Chicago | Conditions: Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 2 | Status: RECRUITING